ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2022
Neutralization of Variant Under Investigation B.1.617.1 With Sera of BBV152 Vaccinees.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 151 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
151 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Implication of the emergence of the delta (B.1.617.2) variants on vaccine effectiveness.Infection · 2022Pooled it
- Postvaccination SARS-CoV-2 infection among healthcare workers: A systematic review and meta-analysis.Journal of medical virology · 2022Pooled it
- Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape.Frontiers in immunology · 2021Pooled it
- Persistence of immunity and impact of third dose of inactivated COVID-19 vaccine against emerging variants.Scientific reports · 2022Trial
- Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial.Lancet (London, England) · 2021Trial
- Low-frequency CD8NPJ vaccines · 2024Article
- Utilizing Feline Lentiviral Infection to Establish a Translational Model for COVID-19 in People with Human Immunodeficiency Virus Infection.Microorganisms · 2024Article
- Review
- Article
- Article
- Review
- Understanding the challenges to COVID-19 vaccines and treatment options, herd immunity and probability of reinfection.Journal of Taibah University Medical Sciences · 2023Review
- Highly Networked SARS-CoV-2 Peptides Elicit T Cell Responses with Enhanced Specificity.ImmunoHorizons · 2023Article
- Article
- Insight into the liver dysfunction in COVID-19 patients: Molecular mechanisms and possible therapeutic strategies.World journal of gastroenterology · 2023Review
- Variants of SARS-CoV-2: Influences on the Vaccines' Effectiveness and Possible Strategies to Overcome Their Consequences.Medicina (Kaunas, Lithuania) · 2023Review
- Review
- Sequence analysis of SARS-CoV-2 Delta variant isolated from Makassar, South Sulawesi, Indonesia.Heliyon · 2023Article
- Delta variant (B.1.617.2) of SARS-CoV-2: current understanding of infection, transmission, immune escape, and mutational landscape.Folia microbiologica · 2023Review
- Risk of hospitalization and vaccine effectiveness among COVID-19 patients in the UAE during the Delta and Omicron outbreaks.Frontiers in immunology · 2023Article
91 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
33961693What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.